Procurement of Midostaurin from Novartis UK

  • BELFAST HEALTH AND SOCIAL CARE TRUST

F14: Notice for changes or additional information

Notice identifier: 2022/S 000-016642

Procurement identifier (OCID): ocds-h6vhtk-0346aa

Published 17 June 2022, 11:30am



Section one: Contracting authority/entity

one.1) Name and addresses

BELFAST HEALTH AND SOCIAL CARE TRUST

LISBURN ROAD

BELFAST

BT97AB

Contact

Norma Moore

Email

norma.moore@belfasttrust.hscni.net

Country

United Kingdom

NUTS code

UKN06 - Belfast

Internet address(es)

Main address

https://belfasttrust.hscni.net/


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Procurement of Midostaurin from Novartis UK

Reference number

DACPM2022-12

two.1.2) Main CPV code

  • 33000000 - Medical equipments, pharmaceuticals and personal care products

two.1.3) Type of contract

Supplies

two.1.4) Short description

Procurement of Midostaurin from Novartis UK


Section six. Complementary information

six.6) Original notice reference

Notice number: 2022/S 000-016389


Section seven. Changes

seven.1.2) Text to be corrected in the original notice

Section number

IV.1.1

Place of text to be modified

Justification for Type of Procedure

Instead of
Text

Award of a contract without prior publication of a call for competition in the cases listed below

The services can be provided only by a particular economic operator for the following reason:

protection of exclusive rights, including intellectual property rights

Explanation:

These are branded patent protected medicines that are essential to patient care and are available from only one economic operator. BHSCT can confirm that the absence of competition is not a result of the artificial narrowing of the parameters of the procurement.

Read
Text

Award of a contract without prior publication of a call for competition in the cases listed below

The services can be provided only by a particular economic operator for the following reason:

Additional deliveries by the original supplier

Explanation:

These essential medicines are required for continuity of patient care and are only available from one economic operator. BHSCT can confirm that the absence of competition is not a result of the artificial narrowing of the parameters of the procurement.